The European market has shown resilience, with the pan-European STOXX Europe 600 Index ending the week slightly up amid ongoing geopolitical uncertainties and fluctuating oil prices. In this context, investors often seek opportunities in less conventional areas like penny stocks, which despite being an older term, continue to represent potential value in smaller or emerging companies. By identifying those with robust financials and growth potential, investors can uncover promising opportunities within this niche segment of the market.
Top 10 Penny Stocks In Europe
Name
Share Price
Market Cap
Financial Health Rating
Ariston Holding (BIT:ARIS)
€3.914
€1.35B
★★★★★★
2020 Bulkers (OB:2020)
NOK2.936
NOK59.13M
★★★★★☆
Lucisano Media Group (BIT:LMG)
€1.05
€15.6M
★★★★☆☆
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Angler Gaming (DB:0QM)
€0.31
€254.2M
★★★★★★
Verkkokauppa.com Oyj (HLSE:VERK)
€2.22
€100.19M
★★★★★☆
Nurminen Logistics Oyj (HLSE:NLG1V)
€0.864
€69.76M
★★★★★★
High (ENXTPA:HCO)
€3.615
€70.05M
★★★★★★
Deceuninck (ENXTBR:DECB)
€2.05
€283.4M
★★★★★★
Netgem (ENXTPA:ALNTG)
€0.742
€24.85M
★★★★★★
Click here to see the full list of 288 stocks from our European Penny Stocks screener.
Let’s dive into some prime choices out of the screener.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Componenta Corporation is a contract manufacturer of metal components serving markets in Finland, Sweden, Germany, Europe, and internationally with a market cap of €44.98 million.
Operations: The company generates revenue from its Contract Workshop Business, amounting to €115.73 million.
Market Cap: €44.98M
Componenta Corporation, with a market cap of €44.98 million, has shown significant earnings growth, achieving a net income of €8.04 million in 2025 compared to €0.204 million the previous year. The company’s return on equity is high at 23.4%, and its debt is well covered by operating cash flow, indicating strong financial health for a penny stock. Recent developments include securing an additional order worth €20.5 million from the Finnish Defence Forces and providing guidance that suggests improved net sales for 2026 over last year’s €115.73 million revenue, demonstrating potential for continued growth in its sector.
HLSE:CTH1V Debt to Equity History and Analysis as at May 2026
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Kamux Oyj, with a market cap of €63.04 million, operates in the wholesale and retail sectors for used cars across Finland, Sweden, and Germany.
Story Continues
Operations: The company generates revenue primarily from its Retail – Gasoline & Auto Dealers segment, amounting to €875.90 million.
Market Cap: €63.04M
Kamux Oyj, with a market cap of €63.04 million, operates in the used car retail sector across Finland, Sweden, and Germany. Despite generating significant revenue of €875.90 million in 2025, the company remains unprofitable with a net loss of €2.3 million for the year and declining sales compared to previous years. Management changes are underway with new appointments aimed at strengthening leadership; however, both management and board tenure suggest relative inexperience. While Kamux’s debt is well covered by operating cash flow and short-term assets exceed liabilities, its interest coverage remains weak due to ongoing losses.
HLSE:KAMUX Revenue & Expenses Breakdown as at May 2026
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Molecular Partners AG is a clinical-stage biotechnology company focused on designing and developing ankyrin repeat protein therapeutics for oncology treatment in Switzerland, with a market cap of CHF126.08 million.
Operations: There are no reported revenue segments for this clinical-stage biotechnology company focused on ankyrin repeat protein therapeutics.
Market Cap: CHF126.08M
Molecular Partners AG, with a market cap of CHF126.08 million, is a pre-revenue biotechnology firm focused on ankyrin repeat protein therapeutics. The company remains unprofitable and its losses have increased over the past five years at 16.1% annually. Despite this, Molecular Partners has no debt and short-term assets of CHF96.9 million exceed both short- and long-term liabilities, providing financial stability for ongoing operations. Recent announcements highlight promising Phase 1 clinical data for MP0317 in oncology treatment and strategic alliances to advance Radio-DARPin therapeutics development, reflecting potential growth avenues amid high share price volatility.
SWX:MOLN Financial Position Analysis as at May 2026 Next Steps
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HLSE:CTH1V HLSE:KAMUX and SWX:MOLN.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com